Get the Stockscreener App
14.65
1.38%
-0.2105
Aurinia Pharmaceuticals Inc stock is traded at $14.65, with a volume of 302.93K.
It is down -1.38% in the last 24 hours and down -9.59% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$14.86
Open:
$14.79
24h Volume:
302.93K
Relative Volume:
0.22
Market Cap:
$1.93B
Revenue:
$260.11M
Net Income/Loss:
$60.64M
P/E Ratio:
34.07
EPS:
0.43
Net Cash Flow:
$92.29M
1W Performance:
-1.31%
1M Performance:
-9.59%
6M Performance:
+59.47%
1Y Performance:
+82.50%
1-Day Range:
$14.64
$15.10
1-Week Range:
$14.36
$15.19
52-Week Range:
$6.55
$16.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
14.65 | 1.96B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Does Aurinia Pharmaceuticals Inc. offer margin of safetyJuly 2025 Big Picture & Safe Capital Investment Plans - mfd.ru
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Ritholtz Wealth Management Buys Shares of 84,515 Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aug Rallies: Will Aurinia Pharmaceuticals Inc benefit from government policyQuarterly Earnings Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - sharewise.com
Aurinia downgraded at RBC on risk-reward setup - MSN
How Investors May Respond To Aurinia Pharmaceuticals (AUPH) Expanding Autoimmune Pipeline And Deepening Otsuka Collaboration - Sahm
Trading the Move, Not the Narrative: (AUPH) Edition - Stock Traders Daily
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: 9.08% Potential Upside Amid Promising Biotech Innovations - DirectorsTalk Interviews
With 54% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance
How Aurinia Pharmaceuticals Inc. stock responds to policy changesWeekly Earnings Recap & Growth Focused Entry Point Reports - ulpravda.ru
Aurinia Pharmaceuticals (NASDAQ:AUPH) Share Price Passes Above 50-Day Moving AverageHere's Why - MarketBeat
How strong is Aurinia Pharmaceuticals Inc. stock balance sheetJuly 2025 Patterns & Growth Oriented Trade Recommendations - ulpravda.ru
Is Aurinia Pharmaceuticals Inc. stock a top pick in earnings seasonTrade Analysis Report & Precise Swing Trade Entry Alerts - ulpravda.ru
Earnings Report: Why Aurinia Pharmaceuticals Inc. (IKAP) stock stays resilientProfit Target & Weekly Top Gainers Trade List - Улправда
Is Aurinia Pharmaceuticals Inc. (IKAP) stock resilient in recession scenarios2025 Technical Patterns & Low Risk High Reward Ideas - Улправда
Why Aurinia Pharmaceuticals Inc. (IKAP) stock is listed among top recommendationsPortfolio Update Summary & Stock Timing and Entry Methods - Улправда
Why retail investors favor Aurinia Pharmaceuticals Inc. stockSupport Zone Identification & Free High Yield Growth Strategies - Улправда
Aruinia discloses FDA information request on Lupkynis amid top regulator’s exit - MSN
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Riding the Biotech Wave with 8.93% Potential Upside - DirectorsTalk Interviews
RBC Capital Downgrades Aurinia Pharmaceuticals (AUPH) - MSN
Aug Sectors: Why retail investors favor Aurinia Pharmaceuticals Inc. stockTrade Entry Report & Smart Swing Trading Alerts - moha.gov.vn
Aurinia Pharmaceuticals IncCommon Shares (NQ: AUPH - FinancialContent
(AUPH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Down 3.6%Here's Why - MarketBeat
Aurinia Pharmaceuticals (AUPH) Price Target Increased by 34.15% to 16.03 - MSN
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Is a Favorite Amongst Institutional Investors Who Own 54% - 富途牛牛
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: A Biotech Contender with a 4.89% Upside - DirectorsTalk Interviews
Spoke.comAurinia Pharmaceuticals IncCommon Shares (Nasdaq:AUPH) Stock Quote - FinancialContent
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? - AOL.com
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? - sharewise.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) rises 3.1% this week, taking three-year gains to 292% - simplywall.st
Understanding the Setup: (AUPH) and Scalable Risk - Stock Traders Daily
How Aurinia Pharmaceuticals Inc. (IKAP) stock trades pre earningsDebt-to-Equity Ratio Analysis & Watch and Learn From Live Trades - bollywoodhelpline.com
Aurinia Pharmaceuticals stock hits 52-week high at 16.49 USD By Investing.com - Investing.com Australia
Aurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 12-Month HighHere's Why - MarketBeat
Aurinia Pharmaceuticals stock hits 52-week high at 16.49 USD - Investing.com
Why Aurinia Pharmaceuticals Inc. (IKAP) stock gets analyst attentionWeekly Market Outlook & Stock Timing and Entry Methods - Улправда
Chart Watch: Will Aurinia Pharmaceuticals Inc. stock pay special dividendsWall Street Watch & Free Risk Controlled Daily Trade Plans - Улправда
Will Aurinia Pharmaceuticals Inc. stock outperform international peersWeekly Stock Recap & Weekly High Return Stock Opportunities - Bölüm Sonu Canavarı
Is Aurinia Pharmaceuticals Inc. stock supported by innovation pipelineJuly 2025 Sector Moves & Community Verified Watchlist Alerts - DonanımHaber
Is Aurinia Pharmaceuticals Inc. (IKAP) stock undervalued after correction2025 Buyback Activity & Smart Swing Trading Techniques - DonanımHaber
Will Aurinia Pharmaceuticals Inc. stock benefit from automationPortfolio Value Report & Proven Capital Preservation Methods - DonanımHaber
Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Squarepoint Ops LLC - MarketBeat
Marex Group plc Buys Shares of 135,000 Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):